Description
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy.
Therefore, pharmacokinetics study is an important part of the drug development.
PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®.
Many investigational anti-PD-1 mAbs are being developed.
There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics